Alembic Pharmaceuticals Announces Board Approvals and Recommends 600% Dividend for FY 2025-26
Alembic Pharmaceuticals Limited announced that its Board of Directors approved the Standalone and Consolidated Audited Financial Results for the quarter and the financial year ended March 31, 2026. The Board also recommended a dividend of Rs. 12 per Equity Share, equating to 600% for the financial year ended March 31, 2026, subject to shareholder approval.The company provided detailed financial statements for investors, covering the Standalone and Consolidated audited results, along with the Statement of Assets and Liabilities and Consolidated Statement of Cash Flows.
Financial Results Highlights
Standalone Financial Performance
The standalone financial results show key figures for the quarter and the full year ended March 31, 2026, compared to the previous year.The Standalone Statement of Audited Financial Results reveals the following performance indicators (Rs. in Crores):
| Particulars | 31.03.2026 (Audited) | 31.12.2025 (Unaudited) | 31.03.2025 (Audited) | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|---|---|---|
| Revenue from Operations | 1,718.74 | 1,642.24 | 1,570.64 | 6,651.38 | 6,032.63 |
| Other Income | 25.88 | 10.73 | 13.21 | 55.90 | 47.88 |
| Total Income | 1,744.62 | - | 1,744.62 | 6,707.28 | 6,080.51 |
| Total Expenses | 1,546.40 | 1,471.5 | 1,492.29 | 5,484.80 | 5,484.80 |
| Profit Before Tax | 173.46 | 138.78 | 91.56 | 654.11 | 608.59 |
| Profit for the Period | 243.07 | - | 75.34 | 640.42 | 503.19 |
| Total Comprehensive Income | 243.51 | - | 77.16 | 636.74 | 502.05 |
| Earnings per share (in Rs.) | 12.37 | - | 3.83 | 32.58 | 25.60 |
Note: The table above combines the 'Total Income' and 'Total Expenses' figures derived from the respective sections of the standalone results for a clearer comparison.
Consolidated Financial Performance
On the consolidated level, total income increased significantly for the year ended March 31, 2026.The Consolidated Statement of Audited Financial Results shows:
| Particulars | 31.03.2026 (Audited) | 31.12.2025 (Unaudited) | 31.03.25 (Audited) | 31.03.2026 (Audited) | 31.03.2025 (Audited) |
|---|---|---|---|---|---|
| Total Income | 1,873.22 | 1,891.81 | 1,783.83 | 7,399.31 | 6,714.63 |
| Total Expenses | 1,730.94 | 1,686.24 | 1,591.22 | 6,638.61 | 6,021.19 |
| Profit Before Tax | 118.62 | 161.50 | 191.95 | 693.95 | 707.18 |
| Profit for the Period | 202.70 | 132.97 | 156.89 | 674.77 | 583.42 |
| Total Comprehensive Income | 213.07 | 139.90 | 162.17 | 695.69 | 587.54 |
Balance Sheet and Cash Flow Summary
The Balance Sheet data provides a snapshot of the company's assets and liabilities.Consolidated Statement of Assets and Liabilities (Rs in Crores)
| Particulars | As at 31st March, 2026 (Audited) | As at 31st March, 2025 (Audited) |
|---|---|---|
| TOTAL ASSETS | 8,762.59 | 7,772.94 |
| Non-current assets: | ||
| Property, plant and equipment | 2,843.59 | 2,523.53 |
| Capital work-in-progress | 633.70 | 837.23 |
| Other Intangible assets | 237.08 | - |
| Intangible assets under development | 49.70 | - |
| Investments (net) | 113.17 | 101.49 |
| Deferred tax assets (net) | 269.61 | 155.05 |
| Other non-current assets | 15.43 | 31.15 |
| Current assets: | ||
| Inventories | 2,510.64 | 2,268.14 |
| Trade receivables | 1,466.30 | 1,399.79 |
| Cash and cash equivalents | 196.37 | 83.48 |
| Other current assets | 338.38 | 287.23 |
| TOTAL EQUITY AND LIABILITIES | 6,762.59 | 7,772.94 |
The Consolidated Statement of Cash Flows for the year ended March 31, 2026, showed the net cash inflow from operating activities at Rs. 782.73 Crores, compared to Rs. 87.97 Crores for the same period in the previous year.
Consolidated Cash Flow Summary (Rs. in Crores)
| Activity | 31.03.2026 | 31.03.2025 |
|---|---|---|
| Net Cash inflow from Operating Activities | 782.73 | 87.97 |
| Net Cash inflow from Investing Activities | 112.69 | (36.73) |
| Net Cash inflow from Financing Activities | (163.79) | 443.71 |
| Net Increase/(Decrease) in Cash and Cash Equivalents | 112.96 | (36.73) |
| Cash and cash equivalents at the end of the period | 196.37 | 83.48 |
Operational and Financial Updates
The company noted several significant financial movements, including recognizing a write-down of Rs. 18.35 crore as an exceptional item due to classifying assets at the Sikkim manufacturing facility as held for sale.Furthermore, the company recognized deferred tax assets aggregating to Rs. 100.27 crore during the quarter, which comprises Rs. 58.46 crore arising from the change in the applicable tax rate and Rs. 41.81 crore relating to tax credits.
Dividend Recommendation
The Board has recommended a dividend of Rs. 12 per equity share, or 600%, for the financial year 2025-26, an increase from the dividend of Rs. 11 per equity share (550%) recommended for the financial year 2024-25.APLLTD Stock Price Movement
Alembic Pharmaceuticals Limited shares today slipped by 0.01% to settle at ₹785.65. The equity saw a total trading volume of 327,819 shares as the market wrapped up trading for the day.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.